UCB SA (EBR:UCB)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 33.30B |
| Revenue (ttm) | 6.15B |
| Net Income (ttm) | 1.07B |
| Shares Out | 190.04M |
| EPS (ttm) | 5.48 |
| PE Ratio | 31.98 |
| Forward PE | 24.10 |
| Dividend | 1.39 (0.77%) |
| Ex-Dividend Date | Apr 26, 2024 |
| Volume | 244,552 |
| Average Volume | 349,380 |
| Open | 178.90 |
| Previous Close | 179.45 |
| Day's Range | 174.65 - 180.80 |
| 52-Week Range | 112.15 - 198.95 |
| Beta | 0.34 |
| RSI | 41.52 |
| Earnings Date | Feb 27, 2025 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]
Financial Performance
In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.
Financial StatementsNews
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders
On Friday, UCB SA (OTC: UCBJY) (OTC: UCBJF) announced further long-term data from the Phase 3 trials and their open-label extensions, investigating Bimzelx (bimekizumab) in adults with moderate-to- ...
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
Over half of patients had no draining tunnels (DTs) at two years: In 425 hidradenitis suppurativa (HS) patients with ≥1 DTs at baseline, 55.7% (195/350) had no DTs at two years of treatment. ≠ DTs are...
UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations Drive Success
Full Year 2024 Ucb SA Earnings Call Transcript
Full Year 2024 Ucb SA Earnings Call Transcript
Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight
Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight
United Community Banks, Inc. (UCB) Q4 2024 Earnings Call Transcript
United Community Banks, Inc. (NYSE:UCB) Q4 2024 Earnings Call January 22, 2025 9:00 AM ETCompany ParticipantsLynn Harton - Chairman and CEOJefferson...
United Community Banks Non-GAAP EPS of $0.63 beats by $0.07, revenue of $239.47M misses by $3.26M
United Community Banks (UCB) reports Q4 Non-GAAP EPS beating expectations by $0.07, but revenue missing by $3.26M, up 44.5% Y/Y.
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
BIMZELX ® (bimekizumab-bkzx) is now commercially available by prescription in the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX The single-injection dev...
United Community Banks Inc (UCB) Announces Upcoming Fourth Quarter 2024 Financial Results Release
United Community Banks Inc (UCB) Announces Upcoming Fourth Quarter 2024 Financial Results Release
United Community Banks to acquire ANB Holdings in an all-stock deal
Financial holding company United Community Banks (UCB) is set to acquire ANB Holdings, and the unit American National Bank, in an all-stock transaction.
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
On Tuesday, UCB SA (OTC: UCBJY) (OTC: UCBJF) and Biogen Inc. (NASDAQ: BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ery...
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
On Wednesday, the FDA approved UCB SA’s (OTC: UCBJY) (OTC: UCBJF) Bimzelx (bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx is the first and only ...
UCB gets FDA approval for Bimzelx for hidradenitis suppurativa
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
United Community Banks: Too Rich For My Blood
United Community Banks' balance sheet shows mixed results in deposits and debt. Read more to see why I think UCB stock is a sell.
Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy
UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more about UCBJF stock here.
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
Clinically meaningful improvements observed with BIMZELX over one year of treatment were maintained up to two years (Week 96) At Week 96, over eight in 10 patients treated with BIMZELX achieved HiSCR5...
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
Responder analyses demonstrated that approximately nine out of 10 patients treated with BIMZELX who achieved PASI90 at Year 1, and over seven out of 10 patients who achieved complete skin clearance (P...
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
Biogen Inc.’s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial
Biogen, UCB mark late-stage trial win for autoimmune disease therapy
Biogen (BIIB) and UCB (UCBJY) announce a Phase 3 trial win for an experimental therapy targeting Systemic Lupus Erythematosus (SLE). Read more here.
UCB gets expanded FDA approval for psoriasis drug Bimzelx
UCB (UCBJY) (UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, ankylosing spondylitis, and nr-axSpA. Read more here.
Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
European biopharmaceutical company UCB SA (OTC: UCBJF) (OTC: UCBJY) announced a $680 million strategic divestment deal in China. The transaction involves the sale, divestment, and license of UCB’s m...
Abu Dhabi fund Mubadala invests in UCB Pharma's China carve-out
The sovereign fund partners with Asia's healthcare investor to acquire 100% in the carve-out
Belgium's UCB to sell China neurology and allergy business for $680 mln
UCB, a Belgian biopharmaceutical firm, said on Monday that it will sell its Chinese neurology and allergy business to asset management group CBC and Abu Dhabhi's Mubadala for $680 million.